Long-acting Beta-agonists Market Outlook:
Long-acting Beta-agonists Market size was USD 11.3 billion in 2025 and is anticipated to reach USD 17.9 billion by the end of 2035, increasing at a CAGR of 5.3% during the forecast period, i.e., 2026-2035. In 2026, the industry size of long-acting beta-agonists is evaluated at USD 11.9 billion.
The international demand for the market is effectively fueled by a rise in population across different nations, who are readily being affected by chronic obstructive pulmonary disease as well as asthma. According to an article published by America Lung Association in July 2024, an estimated 3,517 people died from asthma, which is positively impacting the market’s development. Besides, there has been a decrease in the death rate from 1.7 per 100,000 population to 1.0 over the past four years. In addition, 59% of asthma-based deaths were prevalent among women, and the death rate was 27% higher among women in comparison to the male population.
Furthermore, as per an article published by the World Health Organization (WHO) in November 2024, chronic obstructive pulmonary disease (COPD) is considered the fourth leading cause of death, resulting in 3.5 million deaths, which is 5% of the overall deaths. In addition, almost 90% of COPD deaths take place within 70 years of age, particularly across low- and middle-income countries (LMIC), which is also uplifting the long-acting beta-agonists (LABA) market. Besides, tobacco smoking caters to more than 70% of COPD cases in developed countries, while in developing nations, it accounts for 30% to 40% of COPD cases, thereby making it suitable for bolstering the overall market.
